Viewing nowCombinationEsca Tablet 10/40 mg
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.

MFDS item code 201906433 · Approved 2019.09.11 · Insurance code 644004370
Treatment of essential hypertension not controlled with monotherapy
This medication is a suitable treatment for patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy of amlodipine or olmesartan medoxomil. It works by dilating blood vessels, reducing blood pressure, thereby decreasing the burden on the heart and blood vessels. Consequently, it helps with effective management of essential hypertension and reduces the risk of complications. Depending on the patient's blood pressure control status, dosage adjustments or combination therapy may be necessary. This treatment aims for stable blood pressure maintenance and health improvement.
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Be Administered This Medicine under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose, and consider the patient's renal or cardiac function and comorbidities when adjusting the dose. In elderly patients, blood pressure should be monitored closely and more frequently.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This drug can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, if pregnancy is confirmed, it should be stopped immediately. Patients with allergies to this medication, severe liver disease, severe aortic stenosis, biliary obstruction, those undergoing kidney dialysis, in a state of shock, certain diabetic patients, and those with severely impaired kidney function should not take this medication. Patients with low fluid volume or sodium may experience hypotension, so their status should be carefully monitored during use, and appropriate measures taken if blood pressure decreases. Due to the risk of rapid blood pressure drop from vasodilation, caution should be exercised in patients with aortic stenosis or severe obstructive coronary artery disease. Precaution is required for patients with heart failure, and regular tests are necessary as renal function changes may occur in patients with impaired kidney function. Patients with liver dysfunction should also be cautious when taking this medication. While taking this medication, side effects such as dizziness, headache, hypotension, edema, dyspepsia may occur; if these symptoms persist or worsen, consultation with a doctor is advised. Women who are pregnant or planning to become pregnant should choose other therapies with confirmed safety instead of this medication, and breastfeeding women should consider stopping breastfeeding or the medication as adverse reactions may occur in infants. This medication is not recommended for children under 18 years of age as safety and effectiveness have not been established. Elderly patients should start with a low dose, considering renal and liver function decline, and should be cautious about drug interactions. Overdose may present symptoms such as hypotension and increased heart rate; in such cases, immediate medical assistance is necessary. This drug should be stored in a tightly sealed container out of direct sunlight and moisture, and kept out of the reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is essential to maintain a storage temperature between 1 to 30 degrees Celsius.
Brownish-red round film-coated tablets
28 tablets/Alu-Alu[(14 tablets/Alu-Alu packaging x 2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Samik Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.